A5401 COVID Supplement

A5401 新冠肺炎补充剂

• 批准号: 10203227
• 负责人: Grace M Aldrovandi
• 金额: $ 377万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-09 至 2021-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10203227
• 关键词: AIDS clinical trial group; AIDS/HIV problem; Address; Biological Assay; Biological Markers; COVID-19; Clinical; Clinical Research; Clinical Trials; Collaborations; DNA Repository; Evaluation; Genomics; HIV; Health; Immunology; International; Knowledge; Laboratories; Laboratory Research; Lead; Leadership; Measures; Monoclonal Antibodies; Outpatients; Pathogenesis; Patients; Pharmacology; Procedures; Protocols documentation; Research; Research Personnel; Research Priority; Research Support; Safety; Scientific Advances and Accomplishments; Severe Acute Respiratory Syndrome; Site; Specimen; Speed; Standardization; Testing; Therapeutic; Therapeutic Intervention; Total Quality Management; Training Programs; United States National Institutes of Health; base; coronavirus disease; data management; human DNA; improved; innovation; laboratory experience; novel; operation; programs; small molecule; therapeutic vaccine; treatment guidelines

ABSTRACT The AIDS Clinical Trials Group (ACTG) has been selected to lead a Master Adaptive protocol under the Accelerating COVID-19 Therapeutic Interventions and Vaccine (ACTIV) Operation Warp Speed. This trial (ACTG 5401 or ACTIV-2) will evaluate multiple monoclonal antibodies and other small molecules for outpatient COVID treatment. The Laboratory Center will expand its efforts to include support for COVID-19 clinical trials.

摘要 艾滋病临床试验组（ACTG）已被选中领导一个主适应协议， 加快COVID-19治疗干预和疫苗（ACTIV）操作曲速。本试验 (ACTG 5401或ACTIV-2）将评估门诊患者的多种单克隆抗体和其他小分子 COVID治疗。实验室中心将扩大其努力，包括支持COVID-19临床试验。